

TOXICOLOGICAL PROFILE FOR
PYRIDINE

Agency for Toxic Substances and Disease Registry
U.S. Public Health Service

September 1992

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Register on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

(A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.

(C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.


The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



William L. Roper, M.D., M.P.H.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTENTS

FOREWORD	iii
LIST OF FIGURES	ix
LIST OF TABLES	xi
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS PYRIDINE?	1
1.2 HOW MIGHT I BE EXPOSED TO PYRIDINE?	1
1.3 HOW CAN PYRIDINE ENTER AND LEAVE MY BODY?	2
1.4 HOW CAN PYRIDINE AFFECT MY HEALTH?	2
1.5 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO PYRIDINE?	3
1.6 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	3
1.7 WHERE CAN I GET MORE INFORMATION?	3
2. HEALTH EFFECTS	5
2.1 INTRODUCTION	5
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	5
2.2.1 Inhalation Exposure	6
2.2.1.1 Death	6
2.2.1.2 Systemic Effects	6
2.2.1.3 Immunological Effects	6
2.2.1.4 Neurological Effects	9
2.2.1.5 Developmental Effects	9
2.2.1.6 Reproductive Effects	9
2.2.1.7 Genotoxic Effects	9
2.2.1.8 Cancer	9
2.2.2 Oral Exposure	9
2.2.2.1 Death	9
2.2.2.2 Systemic Effects	10
2.2.2.3 Immunological Effects	14
2.2.2.4 Neurological Effects	14
2.2.2.5 Developmental Effects	15
2.2.2.6 Reproductive Effects	15
2.2.2.7 Genotoxic Effects	15
2.2.2.8 Cancer	15
2.2.3 Dermal Exposure	15
2.2.3.1 Death	15
2.2.3.2 Systemic Effects	16
2.2.3.3 Immunological Effects	16
2.2.3.4 Neurological Effects	16
2.2.3.5 Developmental Effects	16
2.2.3.6 Reproductive Effects	16
2.2.3.7 Genotoxic Effects	16
2.2.3.8 Cancer	16

2.2.4	Other Routes of Exposure	16
2.2.4.1	Death	16
2.2.4.2	Systemic Effects	17
2.2.4.3	Immunological Effects	17
2.2.4.4	Neurological Effects	17
2.2.4.5	Developmental Effects	17
2.2.4.6	Reproductive Effects	17
2.2.4.7	Genotoxic Effects	17
2.2.4.8	Cancer	17
2.3	TOXICOKINETICS	18
2.3.1	Absorption	18
2.3.1.1	Inhalation Exposure	18
2.3.1.2	Oral Exposure	18
2.3.1.3	Dermal Exposure	18
2.3.2	Distribution	18
2.3.2.1	Inhalation Exposure	18
2.3.2.2	Oral Exposure	18
2.3.2.3	Dermal Exposure	18
2.3.3	Metabolism	19
2.3.4	Excretion	19
2.3.4.1	Inhalation Exposure	19
2.3.4.2	Oral Exposure	21
2.3.4.3	Dermal Exposure	21
2.3.4.4	Other Routes of Exposure	21
2.4	RELEVANCE TO PUBLIC HEALTH	21
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	25
2.5.1	Biomarkers Used to Identify and/or Quantify Exposure to Pyridine	27
2.5.2	Biomarkers Used to Characterize Effects Caused by Pyridine	27
2.6	INTERACTIONS WITH OTHER CHEMICALS	27
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	27
2.8	MITIGATION OF EFFECTS	28
2.9	ADEQUACY OF THE DATABASE	29
2.9.1	Existing Information on Health Effects of Pyridine	29
2.9.2	Data Needs	29
2.9.3	On-going Studies	34
3.	CHEMICAL AND PHYSICAL INFORMATION	35
3.1	CHEMICAL IDENTITY	35
3.2	PHYSICAL AND CHEMICAL PROPERTIES	35
4.	PRODUCTION, IMPORT, USE, AND DISPOSAL	39
4.1	PRODUCTION	39
4.2	IMPORT/EXPORT	39
4.3	USE	39
4.4	DISPOSAL	41
5.	POTENTIAL FOR HUMAN EXPOSURE	43
5.1	OVERVIEW	43
5.2	RELEASES TO THE ENVIRONMENT	43

5.2.1	Air	43
5.2.2	Water	46
5.2.3	Soil	46
5.3	ENVIRONMENTAL FATE	46
5.3.1	Transport and Partitioning	46
5.3.2	Transformation and Degradation	48
5.3.2.1	Air	48
5.3.2.2	Water	48
5.3.2.3	Soil	49
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	49
5.4.1	Air	49
5.4.2	Water	49
5.4.3	Soil	50
5.4.4	Other Environmental Media	50
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	50
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	51
5.7	ADEQUACY OF THE DATABASE	51
5.7.1	Data Needs	51
5.7.2	On-going Studies	53
6.	ANALYTICAL METHODS	55
6.1	BIOLOGICAL MATERIALS	55
6.2	ENVIRONMENTAL SAMPLES	56
6.3	ADEQUACY OF THE DATABASE	56
6.3.1	Data Needs	56
6.3.2	On-going Studies	60
7.	REGULATIONS AND ADVISORIES	61
R.	REFERENCES	63
9.	GLOSSARY	79
APPENDICES		
A.	USER'S GUIDE	A-1
B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.	B-1
C.	PEER REVIEW.	C-1



LIST OF FIGURES

2-1	Levels of Significant Exposure to Pyridine - Inhalation	8
2-2	Levels of Significant Exposure to Pyridine - Oral	12
2-3	Proposed Metabolic Pathway for Pyridine	20
2-4	Existing Information on Health Effects of Pyridine	30
5-1	Frequency of NPL Sites with Pyridine Contamination	44

LIST OF TABLES

2-1	Levels of Significant Exposure to Pyridine - Inhalation	7
2-2	Levels of Significant Exposure to Pyridine - Oral	11
2-3	Genotoxicity of Pyridine <u>In Vitro</u>	26
3-1	Chemical Identity of Pyridine	36
3-2	Physical and Chemical Properties of Pyridine	37
4-1	Facilities that Manufacture or Process Pyridine	40
5-1	Releases to the Environment from Facilities That Manufacture or Process Pyridine	45
6-1	Analytical Methods for Determining Pyridine in Biological Materials	57
6-2	Analytical Methods for Determining Pyridine in Environmental Samples	58
7-1	Regulations and Guidelines Applicable to Pyridine	62